DrugPatentWatch Database Preview
Details for Patent: 6,500,454
» See Plans and Pricing
Which drugs does patent 6,500,454 protect, and when does it expire?
Patent 6,500,454 protects INNOPRAN XL and is included in one NDA.
This patent has fourteen patent family members in eleven countries.
Summary for Patent: 6,500,454
| Title: | Timed, sustained release systems for propranolol |
| Abstract: | A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration--time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations. |
| Inventor(s): | Percel; Phillip J. (Troy, OH), Vishnupad; Krishna S. (Dayton, OH), Venkatesh; Gopi M. (Dayton, OH) |
| Assignee: | Eurand Pharmaceuticals Ltd. (IE) |
| Application Number: | 09/971,167 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; Device; Composition; Use; Delivery; |
Drugs Protected by US Patent 6,500,454
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms Inc | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-001 | Mar 12, 2003 | BX | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Ani Pharms Inc | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-002 | Mar 12, 2003 | BX | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,500,454
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 442134 | Start Trial | |||
| Australia | 2002330211 | Start Trial | |||
| Canada | 2462637 | Start Trial | |||
| Germany | 60233668 | Start Trial | |||
| European Patent Office | 1432411 | Start Trial | |||
| Spain | 2333306 | Start Trial | |||
| Japan | 2005508922 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
